0.36
+0.0022(+0.61%)
Currency In USD
| Previous Close | 0.36 |
| Open | 0.36 |
| Day High | 0.37 |
| Day Low | 0.36 |
| 52-Week High | 2.69 |
| 52-Week Low | 0.29 |
| Volume | 75,460 |
| Average Volume | 395,775 |
| Market Cap | 8.38M |
| PE | -0.13 |
| EPS | -2.73 |
| Moving Average 50 Days | 0.35 |
| Moving Average 200 Days | 0.42 |
| Change | 0 |
If you invested $1000 in Turnstone Biologics Corp. (TSBX) since IPO date, it would be worth $32.91 as of July 18, 2025 at a share price of $0.362. Whereas If you bought $1000 worth of Turnstone Biologics Corp. (TSBX) shares 1 year ago, it would be worth $152.74 as of July 18, 2025 at a share price of $0.362.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
GlobeNewswire Inc.
May 08, 2025 10:00 PM GMT
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with sol
Turnstone Biologics Announces Plans to Explore Strategic Alternatives
GlobeNewswire Inc.
Feb 04, 2025 2:00 PM GMT
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) today announced that it has completed an assessment of its business and operations, including the status of its program, resources,
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire Inc.
Nov 05, 2024 2:01 PM GMT
Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluat